Avi Biopharma Inc Sample Contracts

EMPLOYMENT AGREEMENT
Employment Agreement • January 28th, 1997 • Antivirals Inc • Oregon
AutoNDA by SimpleDocs
AVI BioPharma, Inc. UNDERWRITING AGREEMENT
Underwriting Agreement • August 24th, 2009 • Avi Biopharma Inc • Pharmaceutical preparations • New York
COMMON STOCK PURCHASE WARRANT AVI BIOPHARMA, INC.
Common Stock Purchase Warrant • January 30th, 2009 • Avi Biopharma Inc • Pharmaceutical preparations

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the six month anniversary of the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from AVI Biopharma, Inc., an Oregon corporation (the “Company”), up to shares (the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • January 30th, 2009 • Avi Biopharma Inc • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of January 29, 2009, between AVI BioPharma, Inc., an Oregon corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

SAREPTA THERAPEUTICS, INC., as Issuer AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of September 16, 2022 1.250% Convertible Senior Notes due 2027
Indenture • September 19th, 2022 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York

INDENTURE dated as of September 16, 2022 between SAREPTA THERAPEUTICS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01).

RECITALS
Purchase Agreement • January 25th, 2000 • Avi Biopharma Inc • Pharmaceutical preparations • New York
LICENSE AGREEMENT
License Agreement • August 7th, 1998 • Antivirals Inc • Pharmaceutical preparations
ANTIVIRALS INC.
Registration Rights Agreement • January 28th, 1997 • Antivirals Inc • Oregon
To: Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, MA 02142 Attention: General Counsel Telephone No.: (617) 274-4000 From: Mizuho Markets Americas LLC Re: Additional Call Option Transaction Date: September 14, 2022
Sarepta Therapeutics, Inc. • September 19th, 2022 • Pharmaceutical preparations

The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between Mizuho Markets Americas LLC (“Dealer”) (with Mizuho Securities USA LLC acting as agent (in such capacity, the “Agent”)) and Sarepta Therapeutics, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. Each party further agrees that this Confirmation together with the Agreement evidence a complete binding agreement between Counterparty and Dealer as to the subject matter and terms of the Transaction to which this Confirmation relates, and shall supersede all prior or contemporaneous written or oral communications with respect thereto. Dealer is acting as principal hereunder and Agent, its affiliate, is acting as agent for Dealer and Counterparty hereunder. This Confirmation is a confirmation for purposes

RECITALS:
Employment Agreement • March 30th, 1998 • Antivirals Inc • Pharmaceutical preparations • Oregon
PURCHASE AGREEMENT
Purchase Agreement • December 21st, 1999 • Avi Biopharma Inc • Pharmaceutical preparations • New York
2,604,167 Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 par value) EQUITY UNDERWRITING AGREEMENT
Underwriting Agreement • March 7th, 2019 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
CONFIDENTIAL Dr. Leslie Hudson Ph.D CEO and President AVI Biopharma, Inc. One SW Columbia Street Suite 1105 Portland, OR 97258 Dear Dr. Hudson:
Avi Biopharma Inc • January 30th, 2009 • Pharmaceutical preparations • New York

This letter (the “Agreement”) constitutes the agreement between Rodman & Renshaw, LLC (“Rodman” or the “Placement Agent”) and AVI Biopharma, Inc. (the “Company”), that Rodman shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis in connection with the proposed placement (the “Placement”) of registered securities (the “Securities”) of the Company, including shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), with targeted aggregate gross proceeds of $16 million and warrants to purchase shares of Common Stock (“Investor Warrants”). The terms of such Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Rodman would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. Th

LEASE by and between BMR-3450 MONTE VILLA PARKWAY LLC, a Delaware limited liability company and AVI BIOPHARMA, INC., an Oregon corporation
Lease • November 9th, 2009 • Avi Biopharma Inc • Pharmaceutical preparations • Washington

This Access & Confidentiality Agreement (this “Agreement”) is entered into as of [ ], 20[ ] (the “Effective Date”), by and between AVI BIOPHARMA, INC., an Oregon corporation (“AVI”), and [ ] (“Recipient” and, together with AVI, each a “Party” and, together, the “Parties”).

JPMorgan Chase Bank, National Association London Branch Canary Wharf London E14 5JP England
Letter Agreement • November 14th, 2017 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations

The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between JPMorgan Chase Bank, National Association, London Branch (“Dealer”) and Sarepta Therapeutics, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. Each party further agrees that this Confirmation together with the Agreement evidence a complete binding agreement between Counterparty and Dealer as to the subject matter and terms of the Transaction to which this Confirmation relates, and shall supersede all prior or contemporaneous written or oral communications with respect thereto.

SAREPTA THERAPEUTICS, INC. Common Stock ($0.0001 par value per share) AT-THE- MARKET EQUITY OFFERING SALES AGREEMENT
Terms Agreement • July 3rd, 2013 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
RECITALS
Technology Transfer Agreement • June 16th, 2000 • Avi Biopharma Inc • Pharmaceutical preparations • Oregon
CREDIT AND SECURITY AGREEMENT
Credit and Security Agreement • August 3rd, 2017 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
AutoNDA by SimpleDocs
RECITALS:
Employment Agreement • August 7th, 1998 • Antivirals Inc • Pharmaceutical preparations • Oregon
3,817,000 Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 par value) EQUITY UNDERWRITING AGREEMENT
Underwriting Agreement • November 9th, 2018 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
CREDIT AND SECURITY AGREEMENT
Credit and Security Agreement • August 6th, 2015 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York

THIS CREDIT AND SECURITY AGREEMENT (this “Agreement”), dated as of June 26, 2015 (the “Closing Date”) by and among MIDCAP FINANCIAL TRUST, a Delaware statutory trust (“MidCap”), as administrative agent (“Agent”), the Lenders listed on the Credit Facility Schedule attached hereto and otherwise party hereto from time to time (each a “Lender”, and collectively the “Lenders”), and SAREPTA THERAPEUTICS, INC., a Delaware corporation (“Sarepta”), and the other entities shown as signatories hereto as a Borrower (collectively in the singular, “Borrower”), provides the terms on which Lenders agree to lend to Borrower and Borrower shall repay Lenders. The parties agree as follows:

WARRANT AGREEMENT BETWEEN ANTIVIRALS INC.,
Warrant Agreement • March 18th, 1999 • Avi Biopharma Inc • Pharmaceutical preparations • Oregon
AVI BIOPHARMA, INC.
Restricted Stock Unit Award Agreement • April 25th, 2012 • Avi Biopharma Inc • Pharmaceutical preparations • Oregon

Unless otherwise defined herein, the terms defined in the AVI BioPharma, Inc. 2011 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Award Agreement (the “Award Agreement”).

COMMERCIAL LEASE RESEARCH WAY INVESTMENTS
Antivirals Inc • January 28th, 1997
Exchange Agreement
Exchange Agreement • March 3rd, 2023 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
AVI BIOPHARMA, INC. FORM OF INDEMNIFICATION AGREEMENT
Form of Indemnification Agreement • October 8th, 2010 • Avi Biopharma Inc • Pharmaceutical preparations • Oregon

This Indemnification Agreement (this “Agreement”) is dated as of [insert date], and is between AVI BioPharma, Inc., an Oregon corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”).

SAREPTA THERAPEUTICS, INC.
Stock Option Award Agreement • March 3rd, 2014 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • Delaware

Unless otherwise defined herein, the terms defined in the 2014 Employment Commencement Incentive Plan (the “Plan”) will have the same defined meanings in this Stock Option Award Agreement (the “Award Agreement”).

EXHIBIT A
Registration Rights Agreement • September 15th, 2000 • Avi Biopharma Inc • Pharmaceutical preparations • Delaware
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • December 8th, 2003 • Avi Biopharma Inc • Pharmaceutical preparations • New York

SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 4, 2003, by and among AVI Biopharma, Inc., an Oregon corporation, with headquarters located at One SW Columbia Street, Suite 1105, Portland, Oregon 97258 (the “Company”), and the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).

EMPLOYMENT AGREEMENT
Employment Agreement • March 15th, 2011 • Avi Biopharma Inc • Pharmaceutical preparations • Oregon

THIS EMPLOYMENT AGREEMENT (“Agreement”) is made on this 24th day of July, 2008 (the “Effective Date”), by and between AVI BioPharma, Inc., an Oregon corporation, with its principal office at I S.W. Columbia Street, Suite 1100, Portland, Oregon 97258 (“Company”), and J. David Boyle II, 5329 Broadway, Oakland, CA 94618 (“Employee”).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!